<DOC>
	<DOCNO>NCT00002592</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy autologous bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy follow autologous bone marrow transplantation treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy Bone Marrow Transplantation Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate ability c-myb antisense oligodeoxynucleotide purge bone marrow cell clonogenic chronic myelogenous leukemia tumor cell repopulate bone marrow normal stem cell patient treat high-dose busulfan cyclophosphamide follow autologous bone marrow transplantation use marrow treat c-myb antisense oligodeoxynucleotide . II . Determine response rate , degree hematopoietic reconstitution , overall survival , relapse-free survival patient treat regimen . III . Determine toxicity regimen patient . OUTLINE : Patients undergo bone marrow harvest . The bone marrow treat c-myb antisense oligodeoxynucleotide cryopreserved . A portion marrow cryopreserved untreated case engraftment failure . Patients receive oral busulfan every 6 hour day -7 -4 total 16 dos . Patients receive cyclophosphamide IV 1 hour day -3 -2 . Bone marrow reinfused day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 0 continue blood count recover . Patients follow every 2-3 month 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven chronic myelogenous leukemia Accelerated phase OR Chronic phase No hypocellular marrow ( le 25 % cellularity ) No patient age 55 HLAmatched sibling donor PATIENT CHARACTERISTICS : Age : 18 60 Performance status : 01 Hematopoietic : Granulocyte count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST le 3 time normal Renal : Creatinine le 2.0 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : Left ventricular ejection fraction normal No significant cardiac disease require digoxin , diuretic , antiarrhythmic , antianginal medication Pulmonary : PFTs normal DLCO normal Other : No persistent infection require antibiotic No concurrent organ damage medical problem would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 month since prior interferon therapy Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
</DOC>